Gavi supports countries to introduce typhoid conjugate vaccine (TCV) with catch-up campaigns. Available TCVs are highly efficacious, equity-focused, and critical to curbing the expansion of antimicrobial resistance. Four Gavi-supported countries have introduced TCVs since 2018. In the wake of the COVID-19 emergency, momentum is building to scale up TCV introduction worldwide, supported by global partners and Gavi's funding for improved typhoid diagnostics.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10236508 | PMC |
| http://dx.doi.org/10.1093/ofid/ofad042 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Plasmidome of Salmonella enterica serovar Infantis recovered from surface waters in a major agricultural region for leafy greens in California.
PLoS One
January 2025
Produce Safety and Microbiology Unit, Western Regional Research Center, Agricultural Research Service, U.S. Department of Agriculture, Albany, California, United States of America.
Non-typhoidal Salmonella enterica is a leading cause of gastrointestinal illnesses in the United States. Among the 2,600 different S. enterica serovars, Infantis has been significantly linked to human illnesses and is frequently recovered from broilers and chicken parts in the U.
View Article and Find Full Text PDFVariation in plasmid conjugation among non-typhoidal Salmonella enterica serovars.
Can J Microbiol
December 2024
Health Canada, Bureau of Microbial Hazards, Food and Nutrition Directorate, Ottawa, Ontario, Canada;
Conjugation is a complex phenomenon involving multiple plasmid, bacterial, and environmental factors. Here we describe an IncI1 plasmid encoding multidrug antibiotic resistance to aminoglycosides, sulfonamides, and third generation cephalosporins. This plasmid is widespread geographically and among One Health animal, human, and environmental sectors.
View Article and Find Full Text PDFMalawi introduced typhoid conjugate vaccine (TCV) in 2023 through an integrated campaign delivering TCV alongside other vaccines and interventions (measles rubella vaccine (MRV), bivalent oral polio vaccine (OPV), and vitamin A Supplementation). The campaign sought to reach all children 9 months to younger than 14 years, representing more than 9 million individuals, and about half the country's population. Following the campaign, TCV was incorporated into the routine immunization program for 9-month-old infants.
View Article and Find Full Text PDFTyphoid & paratyphoid vaccine development in the laboratory: a review & in-country experience.
Indian J Med Res
December 2024
ICMR-National Institute of Occupational Health, Ahmedabad, Gujarat, India.
Enteric fever is caused by the infection of Gram-negative bacteria, Salmonella enterica serovar Typhi and Salmonella enterica serovar Paratyphi (S. Paratyphi) A, B and C, through contaminated food and water. The disease almost exclusively affects the populations living in low- and middle-income countries, with the World Health Organization Southeast Asian Region (WHO SEAR) having the highest endemicity.
View Article and Find Full Text PDFDesign of a Glycoconjugate Vaccine Against Paratyphi A.
Vaccines (Basel)
November 2024
GSK Vaccines Institute for Global Health (GVGH), 53100 Siena, Italy.
Background/objectives: Typhoid and paratyphoid fever together are responsible for millions of cases and thousands of deaths per year, most of which occur in children in South and Southeast Asia. While typhoid conjugate vaccines (TCVs) are licensed, no vaccines are currently available against Paratyphi A. Here we describe the design of a Paratyphi A conjugate.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!